The biotech looks as if it has a promising treatment for an autoimmune disorder.Wednesday might have been a Hump Day of a slog to some investors, but not for those holding shares of Immunovant (IMVT 10.82%). On some rather encouraging news from the laboratory, the clinical-stage biotech's shares gained almost 11% in value, easily topping the 0.5% rise of the benchmark S&P 500 (^GSPC 0.51%).Proven resultsThat afternoon, Immunovant shared data from a proof-of-concept study of its batoclimab. This is an invest ...